Dilmapimod

Drug Profile

Dilmapimod

Alternative Names: 681323; GSK 681323; SB 681323

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Analgesics; Anti-inflammatories; Antibronchitics; Antirheumatics; Pyrimidines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Atherosclerosis; Chronic obstructive pulmonary disease; Neuropathic pain; Rheumatoid arthritis

Most Recent Events

  • 16 Sep 2009 Efficacy, adverse event and pharmacodynamics data from a phase II trial in Chronic obstuctive pulmonary disease presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
  • 06 Dec 2005 Phase-II clinical trials in Atherosclerosis in the UK
  • 30 Nov 2005 Phase-II clinical trials in Rheumatoid arthritis (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top